Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy

Heart

Volumn 96, Issue 18, 2010, Pages 1475-1479

  D'Alto, Michele ^a   Romeo, Emanuele ^a   Argiento, Paola ^a   Santoro, Giuseppe ^a   Sarubbi, Berardo ^a   Gaio, Giampiero ^a   Mélot, Christian ^b   Russo, Maria Giovanna ^a   Naeije, Robert ^b   Calabrò, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; PROSTACYCLIN; ANTIHYPERTENSIVE AGENT; SULFONAMIDE;

ADULT; ARTICLE; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONGENITAL HEART DISEASE; DISEASE EXACERBATION; DRUG WITHDRAWAL; EDEMA; EISENMENGER COMPLEX; EXERCISE; FEMALE; FOLLOW UP; HEART CATHETER; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PULMONARY VASOREACTIVITY; DIAGNOSTIC USE; DRUG EFFECTS; EPIDEMIOLOGY; EXERCISE TOLERANCE; HEART CATHETERIZATION; HEMODYNAMICS; HYPERTENSION, PULMONARY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; PULMONARY ARTERY; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

ADULT; ANTIHYPERTENSIVE AGENTS; CARDIAC CATHETERIZATION; EISENMENGER COMPLEX; EPIDEMIOLOGIC METHODS; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY ARTERY; SULFONAMIDES; TREATMENT OUTCOME; VASCULAR RESISTANCE; YOUNG ADULT;

EID: 77957110415     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.199661     Document Type: Article

References (20)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians, American Thoracic Society and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94.
3. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11. (Pubitemid 40847788)
4. Skoro-Sajer N, Hack N, Sadushi-Koliçi R, et al. Pulmonary vascular reactivity and prognosis in patients with chronic thromboembolic pulmonary hypertension: a pilot study. Circulation 2009;119:298-305.
5. Budts W, Van Pelt N, Gillyns H, et al. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart 2001;86:553-8. (Pubitemid 32999869)
6. Post MC, Janssens S, Van de Werf F, et al. Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 2004;25:1651-6. (Pubitemid 39209286)
7. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults with Congenital Heart Disease). Circulation 2008;118:e714-833.
8. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007;115:1039-50.
9. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-23.
10. D'Alto M, Vizza CD, Romeo E, et al. Long-term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical and haemodynamic effect. Heart 2007;93:621-5.
11. Winer BJ. Statistical principles in experimental design. 2nd edn. New York: McGraw-Hill, 1971: p514-603.
12. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. 2nd edn. Boston: PWS Publishing Company, 1988:p324-5.
13. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18:533-47.
14. Rabinovitch M, Keane JF, Norwood WI, et al. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation 1984;69:655-67.
15. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958;20:557-70.
16. Bush A, Busst CM, Knight WB, et al. Comparison of the haemodynamic effects of epoprostenol (prostacyclin) and tolazoline. Heart 1988;60:141-8.
17. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates and prognostic implication. Circulation 2005;112:828-35.
18. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996;15:100-5.
19. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.
20. Gatzoulis MA, Beghetti M, Galiè N, et al. BREATHE-5 Investigators. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 2008;127:27-32. (Pubitemid 351707527)